Zynerba Pharmaceuticals Financial Statements (ZYNE)
|
|
|
|
Report date
|
|
|
11.03.2019 |
10.03.2020 |
10.03.2021 |
01.03.2022 |
28.03.2023 |
|
14.08.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.086 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-40.4 |
-34.3 |
-52.1 |
-36.8 |
-35.3 |
|
-38.8 |
|
EBITDA, bln rub |
? |
|
-40.4 |
-34.2 |
-52.1 |
-36.2 |
-34.6 |
|
-38.5 |
|
Net profit, bln rub |
? |
|
-39.9 |
-31.4 |
-50.4 |
-37.6 |
-34.8 |
|
-37.0 |
|
|
OCF, bln rub |
? |
|
-32.4 |
-34.8 |
-41.3 |
-33.5 |
-23.0 |
|
-31.6 |
|
CAPEX, bln rub |
? |
|
0.287 |
0.129 |
0.445 |
0.048 |
0.154 |
|
0.200 |
|
FCF, bln rub |
? |
|
-32.7 |
-34.9 |
-41.8 |
-33.5 |
-23.2 |
|
-31.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
40.5 |
34.3 |
52.1 |
36.8 |
35.3 |
|
38.8 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
27.2 |
20.4 |
35.7 |
21.4 |
21.1 |
|
24.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.216 |
|
0.252 |
|
|
Assets, bln rub |
|
|
67.3 |
87.8 |
74.1 |
81.2 |
55.5 |
|
40.5 |
|
Net Assets, bln rub |
? |
|
57.6 |
75.6 |
60.1 |
70.9 |
46.2 |
|
29.0 |
|
Debt, bln rub |
|
|
0.000 |
0.353 |
0.110 |
0.563 |
0.334 |
|
0.218 |
|
Cash, bln rub |
|
|
59.8 |
70.1 |
59.2 |
67.8 |
50.6 |
|
36.0 |
|
Net debt, bln rub |
|
|
-59.8 |
-69.7 |
-59.0 |
-67.2 |
-50.3 |
|
-35.7 |
|
|
Ordinary share price, rub |
|
|
2.97 |
6.04 |
3.30 |
2.88 |
0.530 |
|
1.21 |
|
Number of ordinary shares, mln |
|
|
15.3 |
22.0 |
27.0 |
39.3 |
42.7 |
|
50.2 |
|
|
Market cap, bln rub |
|
|
45 |
133 |
89 |
113 |
23 |
|
61 |
|
EV, bln rub |
? |
|
-14 |
63 |
30 |
46 |
-28 |
|
25 |
|
Book value, bln rub |
|
|
58 |
76 |
60 |
71 |
46 |
|
29 |
|
|
EPS, rub |
? |
|
-2.61 |
-1.43 |
-1.87 |
-0.96 |
-0.82 |
|
-0.74 |
|
FCF/share, rub |
|
|
-2.13 |
-1.59 |
-1.55 |
-0.85 |
-0.54 |
|
-0.63 |
|
BV/share, rub |
|
|
3.76 |
3.44 |
2.23 |
1.81 |
1.08 |
|
0.58 |
|
|
EBITDA margin, % |
? |
|
-46 974% |
|
|
|
|
|
|
|
Net margin, % |
? |
|
-46 408% |
|
|
|
|
|
|
|
FCF yield, % |
? |
|
-71.9% |
-26.3% |
-46.8% |
-29.6% |
-102.5% |
|
-52.5% |
|
ROE, % |
? |
|
-69.3% |
-41.6% |
-83.8% |
-53.0% |
-75.3% |
|
-127.5% |
|
ROA, % |
? |
|
-59.3% |
-35.8% |
-68.1% |
-46.3% |
-62.7% |
|
-91.4% |
|
|
P/E |
? |
|
-1.14 |
-4.23 |
-1.77 |
-3.01 |
-0.65 |
|
-1.64 |
|
P/FCF |
|
|
-1.39 |
-3.80 |
-2.14 |
-3.37 |
-0.98 |
|
-1.91 |
|
P/S |
? |
|
528.7 |
|
|
|
|
|
|
|
P/BV |
? |
|
0.79 |
1.76 |
1.48 |
1.59 |
0.49 |
|
2.09 |
|
EV/EBITDA |
? |
|
0.35 |
-1.85 |
-0.58 |
-1.27 |
0.80 |
|
-0.65 |
|
Debt/EBITDA |
|
|
1.48 |
2.04 |
1.13 |
1.86 |
1.45 |
|
0.93 |
|
|
R&D/CAPEX, % |
|
|
9 504% |
15 754% |
8 007% |
45 038% |
13 692% |
|
12 348% |
|
|
CAPEX/Revenue, % |
|
|
333.3% |
|
|
|
|
|
|
|
| Zynerba Pharmaceuticals shareholders |
